What Is West Pharmaceutical Services, I (WST) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, West Pharmaceutical Services, I's intrinsic value is estimated at $132.71. Trading at its current price of $359.72, the valuation engine raises significant caution: 12 of 13 models flag downside risk, projecting an average implied return of -63.1%. Model dispersion is worth noting: PWERM targets $347.81 (-3.3%), versus Dynamic NAV at $30.21 (-91.6%). This +88.3% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About WST?
13 of 13 models are currently active for WST. All 13 active models suggest the stock trades above fair value. The Bayesian DCF estimates WST's intrinsic value at $93.08, implying -74.1% downside from the current price. See which stocks rank higher →
How Does WST Rank in Surgical & Medical Instruments & Apparatus?
Among 111 Surgical & Medical Instruments & Apparatus stocks, WST ranks #5 by Quality of Company score. CirclFi's QOC score of 9.9/10 evaluates 32 fundamental signals. A score of 9.9 places WST in the top tier.
See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →
West Pharmaceutical Services, I operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is WST a Value Trap?
CirclFi's Value Trap algorithm assigns WST a score of 8/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for West Pharmaceutical Services, I. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, West Pharmaceutical Services, I earns a quality score of 9.9/10. This exceptional rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +88.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every WST valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across WST's 13 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad